Skip to main content
Erschienen in: Breast Cancer 6/2017

18.03.2017 | Original Article

Cytogenetic analysis of metaplastic squamous cell carcinoma of the breast inter- and intratumoral heterogeneity

verfasst von: Masahiro Oikawa, Akiko Igawa, Kenichi Taguchi, Kimiko Baba, Mayumi Ishida, Sayuri Akiyoshi, Hiroshi Yano, Takeshi Nagayasu, Shinji Ohno, Eriko Tokunaga

Erschienen in: Breast Cancer | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Squamous cell carcinoma (SCC) of the breast is a rare and generally aggressive disease that accounts for less than 0.1% of all breast carcinomas. Although SCCs have distinct morphological features, their origin and cytogenetic profile are not well understood.

Methods

Five patients with SCC were studied. The tumor area that was predominantly composed of SCC components was macrodissected and DNA was extracted. In three cases, an invasive or noninvasive ductal carcinoma of no special type (NST) component was also present. NST-component DNA was also extracted. The tumor DNA was used for array comparative genomic hybridization analysis using a high-density oligonucleotide microarray. The cytogenetic profile of the SCC components was compared with each other and with the paired NST component in three of the five cases.

Results

The cytogenetic profile of the SCC components indicated large intertumoral heterogeneity. There were between 2 and 160 copy number alterations per case, and no common copy number alterations were identified. The cytogenetic profiles of the paired SCC and NST components were similar but not identical. Although, in one case, a larger number of copy number aberrant regions were detected in the SCC component than the NST component. In this case, all the NST component aberrations were present in the SCC component. This implies that the SCC component originated from the NST component. There were no common SCC component-specific aberrations in the three NST-component cases.

Conclusion

Our results demonstrate the cytogenetic inter- and intratumoral heterogeneity of SCC of the breast. Our comparison of cytogenetic profiles indicated that the SCC component originated from the NST component in one case.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Rosen PR. Rosen’s breast pathology. Philadelphia: Lippincott Williams & Wilkins; 2001. Rosen PR. Rosen’s breast pathology. Philadelphia: Lippincott Williams & Wilkins; 2001.
2.
Zurück zum Zitat Grabowski J, Saltzstein SL, Sadler G, Blair S. Squamous cell carcinoma of the breast: a review of 177 cases. Am J Surg. 2009;75(10):914–7. Grabowski J, Saltzstein SL, Sadler G, Blair S. Squamous cell carcinoma of the breast: a review of 177 cases. Am J Surg. 2009;75(10):914–7.
3.
Zurück zum Zitat Hennessy BT, Krishnamurthy S, Giordano S, Buchholz TA, Kau SW, Duan Z, et al. Squamous cell carcinoma of the breast. J Clin Oncol. 2005;23(31):7827–35.CrossRefPubMed Hennessy BT, Krishnamurthy S, Giordano S, Buchholz TA, Kau SW, Duan Z, et al. Squamous cell carcinoma of the breast. J Clin Oncol. 2005;23(31):7827–35.CrossRefPubMed
4.
Zurück zum Zitat Honda M, Saji S, Horiguchi S, Suzuki E, Aruga T, Horiguchi K, et al. Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast. Surg Today. 2011;41(3):328–32.CrossRefPubMed Honda M, Saji S, Horiguchi S, Suzuki E, Aruga T, Horiguchi K, et al. Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast. Surg Today. 2011;41(3):328–32.CrossRefPubMed
5.
Zurück zum Zitat Liu J, Yu Y, Sun JY, He SS, Wang X, Yin J, et al. Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast. Breast Cancer Res Treat. 2015;149(1):133–40.CrossRefPubMed Liu J, Yu Y, Sun JY, He SS, Wang X, Yin J, et al. Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast. Breast Cancer Res Treat. 2015;149(1):133–40.CrossRefPubMed
6.
Zurück zum Zitat The Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer. 17th ed. Tokyo: Kanehara; 2012. The Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer. 17th ed. Tokyo: Kanehara; 2012.
7.
Zurück zum Zitat Lakhani SR EI, Schnitt SJ, Tan PH, van de Vijver MJ (eds). WHO classification of tumours of the breast, 4th edn. 2012, Vol. 4. Lakhani SR EI, Schnitt SJ, Tan PH, van de Vijver MJ (eds). WHO classification of tumours of the breast, 4th edn. 2012, Vol. 4.
8.
Zurück zum Zitat Geyer FC, Weigelt B, Natrajan R, Lambros MB, de Biase D, Vatcheva R, et al. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol. 2010;220(5):562–73.CrossRefPubMed Geyer FC, Weigelt B, Natrajan R, Lambros MB, de Biase D, Vatcheva R, et al. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol. 2010;220(5):562–73.CrossRefPubMed
9.
Zurück zum Zitat Geyer FC, Lambros MB, Natrajan R, Mehta R, Mackay A, Savage K, et al. Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. Mod Pathol. 2010;23(7):951–60.CrossRefPubMed Geyer FC, Lambros MB, Natrajan R, Mehta R, Mackay A, Savage K, et al. Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. Mod Pathol. 2010;23(7):951–60.CrossRefPubMed
10.
Zurück zum Zitat Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.CrossRefPubMed Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.CrossRefPubMed
11.
Zurück zum Zitat Oikawa M, Nagayasu T, Yano H, Hayashi T, Abe K, Kinoshita A, et al. Intracystic papillary carcinoma of breast harbors significant genomic alteration compared with intracystic papilloma: genome-wide copy number and LOH analysis using high-density single-nucleotide polymorphism microarrays. Breast J. 2011;17(4):427–30.CrossRefPubMed Oikawa M, Nagayasu T, Yano H, Hayashi T, Abe K, Kinoshita A, et al. Intracystic papillary carcinoma of breast harbors significant genomic alteration compared with intracystic papilloma: genome-wide copy number and LOH analysis using high-density single-nucleotide polymorphism microarrays. Breast J. 2011;17(4):427–30.CrossRefPubMed
12.
Zurück zum Zitat Oikawa M, Yoshiura K, Kondo H, Miura S, Nagayasu T, Nakashima M. Significance of genomic instability in breast cancer in atomic bomb survivors: analysis of microarray-comparative genomic hybridization. Radiat Oncol. 2011;6:168.CrossRefPubMedPubMedCentral Oikawa M, Yoshiura K, Kondo H, Miura S, Nagayasu T, Nakashima M. Significance of genomic instability in breast cancer in atomic bomb survivors: analysis of microarray-comparative genomic hybridization. Radiat Oncol. 2011;6:168.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009;6(12):718–30.CrossRefPubMed Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009;6(12):718–30.CrossRefPubMed
14.
Zurück zum Zitat Kokufu II, Yamamoto M, Fukuda K, Kitano H, Horioka Y, Tsuji M. Squamous cell carcinoma of the breast: three case reports. Breast Cancer. 1999;6(1):63–8.CrossRefPubMed Kokufu II, Yamamoto M, Fukuda K, Kitano H, Horioka Y, Tsuji M. Squamous cell carcinoma of the breast: three case reports. Breast Cancer. 1999;6(1):63–8.CrossRefPubMed
15.
Zurück zum Zitat Naito Y, Yamaguchi R, Tanaka M, Saruwatari A, Torii Y, Tsukamoto T, et al. Squamous cell carcinoma with apocrine features of the breast: a case report. Oncol Lett. 2014;7(3):647–50.PubMedPubMedCentral Naito Y, Yamaguchi R, Tanaka M, Saruwatari A, Torii Y, Tsukamoto T, et al. Squamous cell carcinoma with apocrine features of the breast: a case report. Oncol Lett. 2014;7(3):647–50.PubMedPubMedCentral
16.
Zurück zum Zitat Okada K, Makihara K, Okada M, Hayashi EI, Fukino S, Fukata T, et al. A case of primary squamous cell carcinoma of the breast with rapid progression. Breast Cancer. 2000;7(2):160–4.CrossRefPubMed Okada K, Makihara K, Okada M, Hayashi EI, Fukino S, Fukata T, et al. A case of primary squamous cell carcinoma of the breast with rapid progression. Breast Cancer. 2000;7(2):160–4.CrossRefPubMed
17.
Zurück zum Zitat Shigekawa T, Tsuda H, Sato K, Ueda S, Asakawa H, Shigenaga R, et al. Squamous cell carcinoma of the breast in the form of an intracystic tumor. Breast Cancer. 2007;14(1):109–12.CrossRefPubMed Shigekawa T, Tsuda H, Sato K, Ueda S, Asakawa H, Shigenaga R, et al. Squamous cell carcinoma of the breast in the form of an intracystic tumor. Breast Cancer. 2007;14(1):109–12.CrossRefPubMed
18.
Zurück zum Zitat Shui R, Li A, Yang F, Zhou X, Yu B, Xu X, et al. Primary squamous cell carcinoma of the breast with unusual basal-HER2 phenotype. Int J Clin Exp Pathol. 2014;7(8):5203–9.PubMedPubMedCentral Shui R, Li A, Yang F, Zhou X, Yu B, Xu X, et al. Primary squamous cell carcinoma of the breast with unusual basal-HER2 phenotype. Int J Clin Exp Pathol. 2014;7(8):5203–9.PubMedPubMedCentral
19.
20.
Zurück zum Zitat Grenier J, Soria JC, Mathieu MC, Andre F, Abdelmoula S, Velasco V, et al. Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Anticancer Res. 2007;27(1B):547–55.PubMed Grenier J, Soria JC, Mathieu MC, Andre F, Abdelmoula S, Velasco V, et al. Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Anticancer Res. 2007;27(1B):547–55.PubMed
21.
Zurück zum Zitat Nozoe T, Mori E, Ninomiya M, Maeda T, Matsukuma A, Nakashima H, et al. Squamous cell carcinoma of the breast. Breast Cancer. 2012;19(2):177–9.CrossRefPubMed Nozoe T, Mori E, Ninomiya M, Maeda T, Matsukuma A, Nakashima H, et al. Squamous cell carcinoma of the breast. Breast Cancer. 2012;19(2):177–9.CrossRefPubMed
22.
Zurück zum Zitat Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472(7341):90–4.CrossRefPubMedPubMedCentral Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472(7341):90–4.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, Chen K, Scheet P, Vattathil S, Liang H, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014;512(7513):155–60.CrossRefPubMedPubMedCentral Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, Chen K, Scheet P, Vattathil S, Liang H, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014;512(7513):155–60.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853):1108–13.CrossRefPubMed Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853):1108–13.CrossRefPubMed
25.
Zurück zum Zitat Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 2009;461(7265):809–13.CrossRefPubMed Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 2009;461(7265):809–13.CrossRefPubMed
26.
Zurück zum Zitat Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464(7291):999–1005.CrossRefPubMedPubMedCentral Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464(7291):999–1005.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Nakao K, Oikawa M, Arai J, Mussazhanova Z, Kondo H, Shichijo K, et al. A predictive factor of the quality of microarray comparative genomic hybridization analysis for formalin-fixed paraffin-embedded archival Tissue. Diagn Mol Pathol. 2013;22(3):174–80.CrossRefPubMed Nakao K, Oikawa M, Arai J, Mussazhanova Z, Kondo H, Shichijo K, et al. A predictive factor of the quality of microarray comparative genomic hybridization analysis for formalin-fixed paraffin-embedded archival Tissue. Diagn Mol Pathol. 2013;22(3):174–80.CrossRefPubMed
Metadaten
Titel
Cytogenetic analysis of metaplastic squamous cell carcinoma of the breast inter- and intratumoral heterogeneity
verfasst von
Masahiro Oikawa
Akiko Igawa
Kenichi Taguchi
Kimiko Baba
Mayumi Ishida
Sayuri Akiyoshi
Hiroshi Yano
Takeshi Nagayasu
Shinji Ohno
Eriko Tokunaga
Publikationsdatum
18.03.2017
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 6/2017
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-017-0768-x

Weitere Artikel der Ausgabe 6/2017

Breast Cancer 6/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.